PharmaVentures appoints senior director
Paul Phull will develop corporate advisory business
PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.
Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.
You may also like
Finance
![Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial]()
Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial
The financing supports a European CTA filing with the EMA for arteriovenous fistula maturation failure in end-stage kidney disease, expanding APAC's clinical programme across thrombo-inflammatory indications
Manufacturing
![AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn]()
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
![GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors]()
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
